控釋藥物遞送市場－全球產業規模、佔有率、趨勢、機會、預測：按技術、釋放機制、應用、地區和競爭格局分類，2021-2031年

全球緩釋製劑市場預計將從 2025 年的 564.5 億美元大幅成長至 2031 年的 1,023.2 億美元，複合年成長率為 10.42%。

這些專用系統透過精確釋放活性成分來維持穩定的治療濃度。推動這一趨勢的主要因素是需要長期照護的慢性疾病發病率不斷上升，以及透過減少給藥頻率來提高患者依從性的需求日益成長。此外，聚合物相容性的不斷進步也有助於實現更有效、更精準的藥物遞送，從而確保市場持續成長。

另一方面，市場擴張的一大障礙是研發所需的大量資金。開發這些複雜的給藥機制涉及大規模臨床試驗和複雜的生產流程，加重了製藥公司的財務負擔。例如，預計到2024年，歐洲以研發為基礎的製藥業將在研發方面投入約550億歐元，凸顯了該領域的資源密集特點，這可能會阻礙中小企業進入市場。

市場促進因素

緩釋製劑市場的主要促進因素是全球慢性疾病（例如癌症和代謝性疾病）發生率的不斷上升，這些疾病需要持續、長期的治療。緩釋系統能有效滿足此需求，使藥物濃度在較長時間內維持在治療範圍內，進而改善患者的治療效果。例如，美國癌症協會預測，到2025年，美國將新增2,041,910例癌症病例，凸顯了對能夠實現精準給藥的先進製劑的需求，並因此推動了緩釋技術的應用。

此外，生物製藥和生物相似藥領域的顯著擴張正在改變藥物傳遞的需求。與小分子藥物不同，這些大分子療法通常需要特殊的遞送機制來防止分解並確保生物利用度。美國食品藥物管理局 (FDA) 在 2024 年核准了 16 種新的生物製劑，佔所有新藥核准的 32%，這反映了這種轉變。因此，像禮來公司這樣的大型製藥企業（該公司在 2025 年的研發累計109.9 億美元）正在加大對新治療方法開發和支持特殊遞送系統的投資。

市場挑戰

由於研發需要大量資金投入，緩釋製劑市場面臨嚴峻的挑戰。建構這些複雜的系統需要精細的製劑製程和大規模的臨床試驗，以確保精確的釋放動力學和病人安全。這導致在產生收入之前需要投入大量資金，從而設置了很高的准入門檻，限制了中小型製藥公司的參與，並將競爭集中在財力雄厚的大型企業之間。

因此，高昂的創新成本限制了新產品的市場推廣。製藥業龐大的研發支出清晰地反映了這一財務負擔。例如，美國製藥商協會（PhRMA）的成員公司在2024年投入了約1,030億美元進行研發。如此龐大的支出正在減緩新型緩釋技術的開發和商業化進程，進而影響全球市場的整體成長軌跡。

市場趨勢

奈米技術，特別是透過先進的脂質奈米顆粒（LNP）技術，其應用範圍正從疫苗擴展到其他領域，並加速更先進的慢性疾病治療方案。新一代LNP旨在實現對特定器官的精準靶向，使mRNA和基因編輯有效載荷能夠遞送到肝臟以外的特定組織。這項技術進步正吸引大量投資，以應對複雜生物製藥的穩定性和製劑方面的挑戰。例如，根據BioXconomy在2025年1月報道，Etherna Immunotherapies NV和Dropshot Therapeutics宣布了一項價值高達9.5億美元的合作計劃，旨在結合雙方在mRNA和LNP領域的專業知識，開發新型RNA療法。

同時，人工智慧 (AI) 正在透過從經驗方法轉向預測建模，變革製劑最佳化方式。製藥公司現在正利用機器學習演算法來精確預測藥物與輔料的相互作用和釋放動力學，從而簡化緩釋系統的開發流程並縮短產品上市時間。這種數位轉型正成為專注於提高研發效率和擴大營運規模的關鍵產業參與者的基礎，例如，根據《臨床研究新聞在線》2025年3月報道，Astra Zeneca在其產品線中廣泛應用生成式人工智慧，以實現其到2030年800億美元的銷售目標。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球控釋藥物遞送市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術（伍斯特法、共鋸齒法、微囊化法、植入、經皮、標靶給藥法等）
  • 釋放機制（聚合物基系統、微儲存庫/隔室控制藥物傳遞系統、回饋控制藥物傳遞系統、活化調節藥物傳遞系統、化學活化系統）
  • 依應用方式（定量吸入器、注射、經皮及眼用貼片、輸液幫浦、口服控釋藥物輸送系統、藥物釋放型支架）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美控釋藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲控釋藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區控釋藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲控釋藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲控釋藥物遞送市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球控釋藥物遞送市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Orbis Biosciences, Inc.
• Merck and Co., Inc.
• Alkermes plc
• Johnson and Johnson
• Coating Place, Inc.
• Corium International, Inc.
• Depomed, Inc.
• Pfizer, Inc
• Aradigm Corporation
• Capsugel Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The global controlled release drug delivery market is projected to expand significantly, from USD 56.45 billion in 2025 to USD 102.32 billion by 2031, demonstrating a 10.42% CAGR. These specialized systems precisely release active pharmaceutical ingredients to sustain consistent therapeutic levels, driven primarily by the escalating incidence of chronic diseases demanding long-term care and a growing need for enhanced patient adherence through less frequent dosing. Additionally, ongoing advancements in polymer compatibility contribute to more effective and targeted drug delivery, ensuring the market's sustained growth.

Conversely, a major obstacle to market expansion is the substantial capital required for research and development. The creation of these intricate delivery mechanisms involves extensive clinical trials and complex manufacturing, increasing financial burdens for pharmaceutical firms. For example, in 2024, the European research-based pharmaceutical industry invested an estimated €55,000 million in R&D, highlighting the considerable resource intensity that can restrict market entry for smaller companies.

Market Driver

A key driver for the controlled release market is the increasing global incidence of chronic diseases, such as oncology and metabolic disorders, which require consistent long-term treatment. Controlled release systems effectively meet this demand by sustaining drug concentrations within the therapeutic range for longer durations, thereby enhancing patient results. For instance, the American Cancer Society projected 2,041,910 new cancer cases in the United States in 2025, underscoring the need for advanced formulations capable of precise delivery, which in turn fuels the adoption of sustained-release technologies.

Furthermore, the significant expansion of the biologics and biosimilars sector is transforming drug delivery needs. These large-molecule therapies often demand specialized delivery mechanisms to protect against degradation and ensure bioavailability, unlike small molecules. In 2024, the FDA approved 16 new biological therapeutics, representing 32% of all novel drug approvals, reflecting this shift. Major pharmaceutical companies like Eli Lilly and Company, which reported $10.99 billion in R&D expenses in 2025, are consequently increasing investments to develop new therapies and supporting specialized delivery systems.

Market Challenge

The controlled release drug delivery market faces a significant challenge due to the considerable capital investment required for research and development. Creating these intricate systems demands complex formulation procedures and extensive clinical trials to guarantee accurate release kinetics and patient safety. This necessitates substantial financial outlay well before revenue generation, establishing a high barrier to entry that restricts smaller pharmaceutical companies and concentrates competition among well-funded, established corporations.

As a result, the elevated cost of innovation limits the introduction of new products into the market. The pharmaceutical sector's substantial R&D expenditure illustrates this financial intensity; for example, Pharmaceutical Research and Manufacturers of America member companies invested roughly $103 billion in R&D in 2024. This extensive spending slows the development and commercialization of novel controlled release technologies, thereby impacting the global market's overall growth trajectory.

Market Trends

Nanotechnology integration, specifically through advanced Lipid Nanoparticles (LNPs), is expanding beyond vaccines to facilitate sophisticated chronic disease treatments. Next-generation LNPs are being engineered for exact organ targeting, enabling the delivery of mRNA and gene-editing payloads to specific tissues beyond the liver. This technological advancement is drawing substantial investment to resolve stability and formulation issues for complex biologics. For example, Etherna Immunotherapies NV and Dropshot Therapeutics announced a collaboration worth up to $950 million to combine their mRNA and LNP expertise for new RNA-based therapeutics, as reported by BioXconomy in January 2025.

Concurrently, artificial intelligence (AI) is transforming formulation optimization by moving from empirical methods to predictive modeling. Pharmaceutical companies are now utilizing machine learning algorithms to accurately predict drug-excipient interactions and release kinetics, which streamlines the development of controlled release systems and shortens time-to-market. This digital shift is becoming a cornerstone for major industry players focused on boosting R&D productivity and scaling operations, as exemplified by AstraZeneca's scaling of generative AI across its pipeline to achieve its $80 billion revenue goal by 2030, according to Clinical Research News Online in March 2025.

Key Market Players

• Orbis Biosciences, Inc.
• Merck and Co., Inc.
• Alkermes plc
• Johnson and Johnson
• Coating Place, Inc.
• Corium International, Inc.
• Depomed, Inc.
• Pfizer, Inc
• Aradigm Corporation
• Capsugel Inc

Report Scope

In this report, the Global Controlled Release Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Controlled Release Drug Delivery Market, By Technology

• Wurster Technique
• Coacervation
• Micro Encapsulation
• Implants
• Transdermal
• Targeted Delivery
• Others

Controlled Release Drug Delivery Market, By Release Mechanism

• Polymer Based Systems
• Micro Reservoir Partition Controlled Drug Delivery Systems
• Feedback Regulated Drug Delivery Systems
• Activation-modulated Drug Delivery Systems
• Chemically Activated

Controlled Release Drug Delivery Market, By Application

• Metered Dose Inhalers
• Injectable
• Transdermal and Ocular Patches
• Infusion Pumps
• Oral Controlled-drug delivery Systems
• Drug Eluting Stents

Controlled Release Drug Delivery Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Controlled Release Drug Delivery Market.

Available Customizations:

Global Controlled Release Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Controlled Release Drug Delivery Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Others)
  • 5.2.2. By Release Mechanism (Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-modulated Drug Delivery Systems, Chemically Activated)
  • 5.2.3. By Application (Metered Dose Inhalers, Injectable, Transdermal and Ocular Patches, Infusion Pumps, Oral Controlled-drug delivery Systems, Drug Eluting Stents)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Controlled Release Drug Delivery Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Release Mechanism
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Controlled Release Drug Delivery Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Release Mechanism
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Controlled Release Drug Delivery Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Release Mechanism
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Controlled Release Drug Delivery Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Release Mechanism
      • 6.3.3.2.3. By Application

7. Europe Controlled Release Drug Delivery Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Release Mechanism
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Controlled Release Drug Delivery Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Release Mechanism
      • 7.3.1.2.3. By Application
  • 7.3.2. France Controlled Release Drug Delivery Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Release Mechanism
      • 7.3.2.2.3. By Application
  • 7.3.3. United Kingdom Controlled Release Drug Delivery Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Release Mechanism
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Controlled Release Drug Delivery Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Release Mechanism
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Controlled Release Drug Delivery Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Release Mechanism
      • 7.3.5.2.3. By Application

8. Asia Pacific Controlled Release Drug Delivery Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Release Mechanism
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Controlled Release Drug Delivery Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Release Mechanism
      • 8.3.1.2.3. By Application
  • 8.3.2. India Controlled Release Drug Delivery Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Release Mechanism
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Controlled Release Drug Delivery Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Release Mechanism
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Controlled Release Drug Delivery Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Release Mechanism
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Controlled Release Drug Delivery Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Release Mechanism
      • 8.3.5.2.3. By Application

9. Middle East & Africa Controlled Release Drug Delivery Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Release Mechanism
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Controlled Release Drug Delivery Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Release Mechanism
      • 9.3.1.2.3. By Application
  • 9.3.2. UAE Controlled Release Drug Delivery Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Release Mechanism
      • 9.3.2.2.3. By Application
  • 9.3.3. South Africa Controlled Release Drug Delivery Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Release Mechanism
      • 9.3.3.2.3. By Application

10. South America Controlled Release Drug Delivery Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Release Mechanism
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Controlled Release Drug Delivery Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Release Mechanism
      • 10.3.1.2.3. By Application
  • 10.3.2. Colombia Controlled Release Drug Delivery Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Release Mechanism
      • 10.3.2.2.3. By Application
  • 10.3.3. Argentina Controlled Release Drug Delivery Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Release Mechanism
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Controlled Release Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Orbis Biosciences, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck and Co., Inc.
• 15.3. Alkermes plc
• 15.4. Johnson and Johnson
• 15.5. Coating Place, Inc.
• 15.6. Corium International, Inc.
• 15.7. Depomed, Inc.
• 15.8. Pfizer, Inc
• 15.9. Aradigm Corporation
• 15.10. Capsugel Inc

16. Strategic Recommendations

17. About Us & Disclaimer